pharmaphorum8m
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand Pharma join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. See why this ...
Novo Nordisk, Lilly Stocks Are Falling. A Rival Weight-Loss Drug Is on the Way.
Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...
Endpoints News53m
Viking Ther­a­peu­tics taps Cor­den­Phar­ma to man­u­fac­ture its obe­si­ty drugs
Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss.
Novo Nordisk Stock Falls After Roche Strikes Weight-Loss Deal
Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Shares in Roche rallied in Europe, while ...